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Herpes Zoster following SARS-
CoV-2 vaccination – a series of
four cases
Dear Editor,
The SARS-CoV-2 pandemic is a global public health crisis, with
significant morbidity, mortality and socio-economical impacts.
Vaccines were developed and granted emergency approvals by
most drug agencies to tackle this crisis, but the safety profile of
these vaccines is not fully clarified.
We present a series of four cases of varicella zoster virus
(VZV) reactivation after vaccination against SARS-CoV-2, who
presented at the Dermatology Department, Centro Hospitalar
Universitario Lisboa Norte, Lisbon (Portugal), from 30 January
2021 to 30 April 2021. The characteristics of each patient are
summarized in Table 1.
Two patients were administered Pfizer’s ComirnatyTM (New
York, NY, USA) vaccine and two were given Astrazeneca Vax-
zevriaTM (Cambridge, UK) vaccine. The onset of complaints var-
ied between 3 and 6 days following the first dose. Three patients
presented with facial herpes zoster, and one patient had reactiva-
tion of VZV on an upper limb dermatome; on the same side, the
vaccine had been administered (Fig. 1). The diagnosis was con-
firmed through polymerase chain reaction of a sample collected
from the vesicles, which identified VZV in every case.
All patients improved under valacyclovir 1000 mg tid, and no
immediate or long-term complications were observed. Patients 2
and 4 received the second dose of the vaccine without any occur-
rences.
Varicella zoster virus reactivation has been described in
patients with COVID-191,2 and after vaccination against hepati-
tis A, rabies and influenza, suggesting a vaccine-induced
immunomodulation.3 Recently, a series of VZV reactivation
cases following ComirnatyTM administration in patients with
rheumatological conditions under immunosuppressive and
immunomodulatory treatments has been published, suggesting a
possible link.4 While that report signals a possible link between
one particular vaccine and VZV reactivation, the fact that all
patients suffered from rheumatological conditions under
immunosuppressant/immunomodulatory treatments limits gen-
eralization of these findings, particularly when the development
programme of these vaccines did not identify this adverse reac-
tion. In our series, all but one patient were otherwise healthy
and not known to have any predisposing factor for VZV reacti-
vation.
From a pathophysiological point of view, VZV reactiva-
tion in COVID-19 may be straightforward to explain, as a
febrile condition where lymphopenia is common seems to
be the ideal setting for VZV reactivation. On the contrary,
the mechanisms behind VZV reactivation following SARS-
CoV-2 vaccination are more elusive. A component of the
vaccine might be responsible for this link; however, Comir-
natyTM and VaxzevriaTM share few ingredients and rely on
different technologies to lead to SARS-CoV-2 Spike-protein
production by the cell. The only shared characteristic
Table 1 Characteristics of the reported cases of varicella zoster virus (VZV) reactivation following vaccination against SARS-CoV-2
Patient # 1 2 3 4
Age 70 73 63 69
Sex Female Female Female Male
Medical conditions Hallux valgus Mechanical
mitral valve
prosthesis






Usual medication – Warfarin – Mycophenolate mofetil 500 mg bid
Hydroxychloroquine 400 mg od
Prednisolone 7.5 mg od





Comirnaty (Pfizer) Comirnaty (Pfizer)
Onset of VZV reactivation
(days after first dose)
3 4 6 3
VZV reactivation site Left V2 territory Right V3
territory
Left C8 territory Left V2/V3 territory
Prior History of
Herpes Zoster







Local pain at administration site
Fever for 24 h
Local pain at administration site
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between the two is indeed the expression of viral Spike pro-
tein to induce immune response.
Spike protein may have pleotropic effects in the host. This
protein was shown to favour syncytium-mediated lymphocyte
elimination5 and phenotypic transition of B-lymphocytes to
macrophage-like cells with poor phagocytosis capability,6 These
effects could be responsible for misbalancing the immune
response that keeps VZV dormant. We stress that all cases
occurred in individuals over 60 years old. Age is the major risk
factor for VZV reactivation in 90% of the cases,7 and the absence
of reports of Herpes Zoster in healthy younger individuals fol-
lowing SARS-CoV-2 vaccines may signify that these vaccines




Figure 1 Clinical photographs of the reported cases. (a) Patient 1; (b) Patient 2; (c) Patient 3; (d) Patient 4.
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Our case series is limited by the absence of a control group
and the retrospective analysis that was conducted. Large-scale
prospective studies and pharmacovigilance monitoring are war-
ranted to clarify the risks of VZV reactivation for all available
SARS-CoV-2 vaccines. It should be determined whether all
SARS-CoV-2 share a similar risk for this adverse reaction and
should some of them be relatively safer in this regard, considera-
tion should be given when choosing a vaccine for individuals
most at risk for VZV reactivation (e.g. elderly, immunosuppres-
sion).
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New onset of mainly guttate
psoriasis after COVID-19
vaccination: a case report
Editor
Psoriasis is a chronic, immune-mediated inflammatory disease
with heterogeneous clinical manifestations. Various trigger fac-
tors like infections and drugs are known to elicit or aggravate
psoriasis. Previously, a possible association of vaccination and
the new onset (particularly guttate lesions) or exacerbation of
psoriasis has been reported.1,2 Herein, we describe a case of
mainly guttate psoriasis after a COVID-19 vaccination.
A 79-year-old female patient was referred to our depart-
ment due to a disseminated itching psoriasiform rash, which
had started 10 days after receiving the first injection with the
COVID-19 vaccination Comirnaty (BioNTech, Freiburg-
strasse, Bern, Switzerland). There was no prior or family his-
tory of psoriasis or any other putative triggers (new intake of
medication, underlying infections). Her past medical history
revealed type-2 diabetes and hypertension and her daily medi-
cations (without any recent adaptations) included sitagliptin/
metformin, empagliflozin, gliclazide, bisoprolol, enalapril,
aspirin and esomeprazole. On examination, there were numer-
ous, disseminated, erythematous papules and partly scaly pla-
ques mainly on the extensor surface of her arms, thighs
(Fig. 1a,b), back and scalp. After some improvement with
topical clobetasol propionate ointment once daily, the second
dose of Comirnaty was given, which again led to a flare-up
particularly on her arms and legs. The patient is currently on
treatment with topical calcipotriol/ betamethasone ointment
and UVB phototherapy.
In order to characterize the skin lesions, histological [Haema-
toxylin & Eosin (H&E) staining] and immunohistochemical
examinations of a lesional punch biopsy specimen were per-
formed. Histopathological examination showed an acanthotic
epidermis with focal loss of the granular cell layer and a compact
hyperparakeratosis alternating with orthokeratosis, as well as
superficial perivascular lymphohistiocytic infiltrates with a few
scattered neutrophils, consistent with guttate psoriasis (Fig. 1c).
Immunohistochemical analysis using the avidin-biotin complex-
alkaline phosphatase (ABC-AP) method was performed with fol-
lowing primary antibodies: CD1a (clone MTB1; Leica Biosys-
tems, Nussloch, Germany), CD4 (clone 4B12; DakoCytomation,
Glostrup, Denmark), CD8 (clone 4B11; Leica Biosystems),
CD11c (clone 5D11; Novocastra, Muttenz, Switzerland), CD32
(clone EPR6657; Abcam, Cambridge, MA, USA), CD68 (clone
PG-M1, DakoCytomation), CD163 (clone EDHU-1; Serotec
MCA, Oxford, UK), CD303/BDCA2 (clone 124B.13, Dendritics,
© 2021 European Academy of Dermatology and VenereologyJEADV 2021, 35, e699–e831
e752 Letters to the Editor
